Antibody Mediated Rejection clinical trials at UCSF
1 research study open to eligible people
Antibody mediated rejection happens when the immune system attacks a transplanted organ. UCSF is conducting trials to test if BIVV020 can prevent this type of rejection. The research looks at how well BIVV020 works in stopping the immune system's attack.
BIVV020 (SAR445088) n Prevention and Treatment of Antibody-mediated Rejection (AMR)
open to eligible people ages 18 years and up
Primary Objectives: - Cohort A: To evaluate the efficacy of BIVV020 in prevention of AMR - Cohort B: To evaluate the efficacy of BIVV020 in treatment of active AMR Secondary Objectives: - To assess the overall efficacy of BIVV020 in prevention or treatment of AMR - To characterize the safety and tolerability of BIVV020 in kidney transplant participants - To characterize the pharmacokinetic (PK) profile of BIVV020 in kidney transplant participants - To evaluate the immunogenicity of BIVV020
San Francisco, California and other locations
Last updated: